NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study
Open Access
- 18 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 12 (1), 24
- https://doi.org/10.1186/1471-2407-12-24
Abstract
Background Cell surface NKG2D ligands (NKG2DL) bind to the activating NKG2D receptor present on NK cells and subsets of T cells, thus playing a role in initiating an immune response. We examined tumor expression and prognostic effect of NKG2DL in breast cancer patients. Methods Our study population (n = 677) consisted of all breast cancer patients primarily treated with surgery in our center between 1985 and 1994. Formalin-fixed paraffin-embedded tumor tissue was immunohistochemically stained with antibodies directed against MIC-A/MIC-B (MIC-AB), ULBP-1, ULBP-2, ULBP-3, ULBP-4, and ULBP-5. Results NKG2DL were frequently expressed by tumors (MIC-AB, 50% of the cases; ULBP-1, 90%; ULBP-2, 99%; ULBP-3, 100%; ULBP-4, 26%; ULBP-5, 90%) and often showed co-expression: MIC-AB and ULBP-4 (p = 0.043), ULBP-1 and ULBP-5 (p = 0.006), ULBP-4 and ULBP-5 (p < 0.001). MIC-AB (p = 0.001) and ULBP-2 (p = 0.006) expression resulted in a statistically significant longer relapse free period (RFP). Combined expression of these ligands showed to be an independent prognostic parameter for RFP (p < 0.001, HR 0.41). Combined expression of all ligands showed no associations with clinical outcome. Conclusions We demonstrated for the first time that NKG2DL are frequently expressed and often co-expressed in breast cancer. Expression of MIC-AB and ULBP-2 resulted in a statistically significant beneficial outcome concerning RFP with high discriminative power. Combination of all NKG2DL showed no additive or interactive effect of ligands on each other, suggesting that similar and co-operative functioning of all NKG2DL can not be assumed. Our observations suggest that among driving forces in breast cancer outcome are immune activation on one site and tumor immune escape on the other site.Keywords
This publication has 27 references indexed in Scilit:
- Upregulation of MICA on high-grade invasive operable breast carcinoma.2007
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007Annals of Oncology, 2007
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patientsInternational Journal of Cancer, 2005
- Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In VivoThe Journal of Immunology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human NeuroblastomaNeoplasia, 2004
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004
- High frequency of altered HLA class I phenotypes in invasive breast carcinomasHuman Immunology, 1996